Menopause Treatments in 2025: What Actually Works (And What Doesn't)

For a long time, the medical conversation around menopause went something like this: hot flashes? Tough it out. Mood swings? Try yoga. Can't sleep? Melatonin, maybe. The idea that menopause symptoms deserved serious medical treatment was almost radical. And for the millions of people who went through the worst of it in the post-2002 era, when a single flawed study scared an entire generation of doctors away from hormone therapy, the message was basically: this is just life now.

That's changing. Fast. The science of menopause treatments in 2025 is genuinely different from what it was even five years ago, and it's worth understanding what's real, what's overhyped, and what the right treatment actually looks like for your specific situation. Because there's no one-size-fits-all answer here, and anyone who tells you otherwise is selling something.

So let's actually dig into it. This guide covers hormone replacement therapy (HRT), non-hormonal medications, lifestyle interventions, and a few emerging therapies, comparing what each does well, where the evidence is solid, and where it's shakier than the internet wants you to believe.

What Menopause Actually Does to Your Body (The Short Version)

Menopause is defined as 12 consecutive months without a menstrual period, typically occurring between ages 45 and 55. But the transition, called perimenopause, can start years earlier, and that's often when things start feeling off. Estrogen and progesterone levels decline, and because these hormones interact with almost every system in your body, the effects are wide-ranging.

We're talking hot flashes and night sweats (vasomotor symptoms, in clinical language), disrupted sleep, mood changes, brain fog, vaginal dryness, joint pain, changes in body composition, and longer-term risks to bone density and cardiovascular health. It's a lot. And not all of it is treated by the same intervention.

That's the most important framing for this whole guide: different symptoms respond to different treatments. The goal isn't to find the one thing that fixes menopause. It's to find the right combination for what you're actually experiencing.

Hormone Replacement Therapy: The Evidence Is Stronger Than You Think

Ready for a brief history lesson that actually matters? In 2002, the Women's Health Initiative (WHI) study published results suggesting HRT increased breast cancer and cardiovascular risk. The headlines were terrifying. HRT prescriptions plummeted. A generation of women was undertreated.

Here's the catch. That study used oral conjugated equine estrogen plus medroxyprogesterone acetate, mostly in women who were already well past menopause, many with pre-existing cardiovascular risk. Later reanalysis showed the risks were much more nuanced, and for women who started HRT within 10 years of menopause onset (or before age 60), the cardiovascular risk picture looked quite different.

The current consensus from the Menopause Society and major endocrinology bodies: for healthy women under 60 who are within 10 years of menopause onset, the benefits of HRT generally outweigh the risks. That's a meaningful shift.

What HRT Actually Treats Well

• Vasomotor symptoms (hot flashes, night sweats): This is HRT's strongest suit. Estrogen therapy reduces hot flash frequency by 75-80% in most clinical trials, far more than any non-hormonal option.
• Genitourinary syndrome of menopause (GSM): Vaginal dryness, urinary urgency, and recurrent UTIs respond well to estrogen, either systemic or local.
• Sleep disruption: When sleep problems are driven by night sweats and vasomotor symptoms, treating those with HRT often restores sleep quality significantly.
• Bone density: Estrogen is one of the most effective preventive interventions for postmenopausal osteoporosis. Studies show it reduces fracture risk by 30-40%.
• Mood and cognitive symptoms: Evidence here is more nuanced, but several trials show HRT reduces depressive symptoms during perimenopause, particularly when initiated early.

The HRT Delivery Method Matters More Than People Realize

Not all HRT is created equal. Oral estrogen is metabolized by the liver, which alters its effect on clotting factors and can modestly increase stroke risk. Transdermal estrogen (patches, gels, creams) bypasses the liver entirely, which is why most current guidelines prefer it for most women.

Similarly, if you have a uterus, you need progestogen alongside estrogen to protect the uterine lining. The type matters: synthetic progestins (like the medroxyprogesterone in the WHI study) have a different risk profile than micronized progesterone, which more closely resembles the body's natural hormone and appears to have a more favorable effect on sleep, mood, and breast cancer risk.

At Healthspan, HRT isn't a one-pill-fits-all prescription. The Women's Hormone Health program includes lab work to assess your baseline hormone levels, a clinician consultation to understand your symptom profile, and access to multiple delivery options, including the Estradiol Patch, Bi-Est 50/50 Cream, and Micronized Progesterone, with ongoing monitoring built in. That last part is what separates a real clinical protocol from ordering something online and hoping for the best.

Non-Hormonal Medications: When HRT Isn't the Right Fit

Not everyone is a candidate for HRT. If you have a history of estrogen-receptor-positive breast cancer, certain clotting disorders, or simply prefer to avoid hormones, there are evidence-backed non-hormonal options. They're not as effective as estrogen for vasomotor symptoms, but some are genuinely useful.

SSRIs and SNRIs

Paroxetine (at a low 7.5 mg dose) is the only FDA-approved non-hormonal treatment specifically for menopausal hot flashes. Venlafaxine and escitalopram also have reasonable evidence behind them. These aren't antidepressants in this context, they work on serotonin and norepinephrine pathways involved in thermoregulation. They reduce hot flash frequency by roughly 40-60%, less effective than estrogen, but meaningful. Note: paroxetine should be avoided if you're on tamoxifen for breast cancer, as it interferes with tamoxifen metabolism.

Fezolinetant

This is genuinely new. Fezolinetant (brand name Veozah) was approved by the FDA in 2023 as the first neurokinin B receptor antagonist for menopause symptoms. It works by blocking the NK3 receptor in the brain's thermoregulatory center, which becomes overactive when estrogen levels drop. Clinical trials showed a 60% reduction in moderate-to-severe hot flash frequency at 12 weeks. It's not cheap, and longer-term data is still accumulating, but it's a legitimate non-hormonal option for vasomotor symptoms specifically.

Gabapentin and Clonidine

These are older options with more modest evidence. Gabapentin reduces hot flashes somewhat and may help sleep, but the side effect profile (dizziness, cognitive fog) is a real concern. Clonidine works, but not especially well, and blood pressure effects limit its use. Most clinicians consider these second- or third-line options.

Low Dose Naltrexone

This one's worth flagging separately. Low dose naltrexone (LDN) isn't approved for menopause symptoms, but there's growing interest in its role in inflammation modulation and mood regulation, which can be relevant in perimenopause. The evidence here is mostly mechanistic and anecdotal rather than from large RCTs, so keep that in mind. Healthspan offers Low Dose Naltrexone (LDN) Troche for appropriate candidates under clinical supervision.

Lifestyle Interventions: Real Effects, Realistic Expectations

Here's what the internet overestimates: that lifestyle changes will replace medical treatment for significant menopause symptoms. Here's what it underestimates: that lifestyle changes have genuinely meaningful, evidence-backed effects on several key areas.

Exercise

Resistance training is arguably the most important lifestyle intervention for menopause, full stop. It preserves muscle mass (which estrogen was partly responsible for maintaining), supports bone density, improves mood, and helps with sleep. A 2024 systematic review found that structured exercise, particularly resistance training combined with aerobic activity, significantly improved quality of life and reduced depressive symptoms in menopausal women. It doesn't touch hot flashes much, but it does a lot of other things.

Diet and Body Composition

Menopause is associated with a shift in fat distribution toward visceral adiposity (the metabolically dangerous kind), even without changes in total body weight. This increases cardiovascular and metabolic risk. Reducing processed carbohydrates, prioritizing protein (to preserve muscle), and managing caloric balance all have clear mechanistic rationale. Some evidence suggests soy isoflavones modestly reduce hot flash frequency, though effects are small and inconsistent across populations.

Sleep Hygiene and CBT-I

Cognitive Behavioral Therapy for Insomnia (CBT-I) has strong evidence for improving sleep in menopausal women, even when vasomotor symptoms are contributing. If your sleep disruption isn't primarily driven by night sweats, CBT-I is often more durable than medication-only approaches. It's worth trying before or alongside pharmacological options.

Stress and the HPA Axis

Chronic stress worsens hot flashes through HPA axis dysregulation. Mindfulness-based stress reduction (MBSR) has modest but real evidence for reducing vasomotor symptom severity, not frequency. It's not going to replace treatment, but it can reduce the intensity of what you're experiencing.

The Reality Check: What We Don't Actually Know Yet

A few things the menopause wellness industry would prefer you didn't hear:

Most of the data on HRT and long-term outcomes (cardiovascular protection, dementia prevention) is observational, not from randomized controlled trials. The "timing hypothesis," the idea that starting HRT early in menopause is protective for the heart and brain, is compelling and consistent, but still not definitively proven in RCTs. We're working from the best evidence available, not certainty.

Bioidentical hormone compounding is a marketing term more than a scientific one. "Bioidentical" simply means the hormone is structurally identical to what your body produces. FDA-approved products like estradiol and micronized progesterone are bioidentical. Custom-compounded hormone creams sold with saliva testing and the implication that they're safer or more natural than regulated products? The evidence for those specific formulations is weak, and they're not FDA-regulated for safety or efficacy. Be skeptical.

Supplements marketed for menopause, black cohosh, evening primrose oil, wild yam, have evidence ranging from "mildly promising" to "basically placebo." They're not dangerous for most people, but they're not the same as treatment.

Emerging Therapies Worth Watching

This is the part of the menopause conversation that's moving fastest.

Testosterone for Women

Low testosterone in women (yes, women have testosterone, and levels decline in menopause) is associated with reduced libido, fatigue, and diminished muscle mass. Evidence for testosterone supplementation improving libido in postmenopausal women is actually quite good, with multiple systematic reviews supporting it. Evidence for the other outcomes is less robust. The challenge is that no testosterone product is currently FDA-approved specifically for women in the US, so prescribing is off-label, which doesn't mean it's wrong, but it does mean clinical supervision matters even more. Healthspan addresses this within the Women's Hormone Health protocol.

Metabolic Interventions

Menopause significantly increases insulin resistance and metabolic risk. Some clinicians are now looking at metformin and SGLT2 inhibitors not just as diabetes drugs but as metabolic support tools in postmenopausal women with elevated metabolic risk. The evidence isn't menopause-specific yet, but the mechanisms are real. Healthspan's Metformin protocol and Canagliflozin (an SGLT2 inhibitor) are available for appropriate candidates as part of broader metabolic health management.

GLP-1 Receptor Agonists

GLP-1 agonists like semaglutide and tirzepatide are showing up everywhere right now, and for postmenopausal women struggling with weight gain (particularly visceral fat accumulation), they're increasingly relevant. Body composition changes in menopause are partly hormonally driven, which is why diet alone often underperforms. GLP-1 agonists address the metabolic side of that equation. Healthspan offers several GLP-1 options through its GLP-1 Longevity Care program, with ongoing clinical monitoring.

Who Is HRT Actually Right For?

The ideal candidate for systemic HRT in 2025 looks something like this: you're between 45 and 60, within 10 years of menopause onset, experiencing moderate-to-severe vasomotor symptoms or other quality-of-life impacts, and you don't have a history of estrogen-sensitive breast cancer, unexplained vaginal bleeding, active liver disease, or a personal history of blood clots (especially with oral estrogen). You've talked to a clinician who's actually reviewed your personal and family history, not just handed you a checklist.

If you're past 60 or more than 10 years postmenopausal, it doesn't mean HRT is automatically off the table, but the risk-benefit calculation shifts, and it requires a more individualized assessment. If you have significant cardiovascular risk factors, transdermal delivery is generally preferred. And if you have a uterus, you need progesterone alongside estrogen, full stop.

Risks and Side Effects: What to Actually Watch For

• Breast cancer: The most-cited risk. Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk, roughly 1 additional case per 1,000 women over 5 years of use. Estrogen alone (in women without a uterus) may not increase risk at all. Micronized progesterone appears to carry lower risk than synthetic progestins.
• Blood clots (VTE): Oral estrogen increases clot risk. Transdermal estrogen does not appear to, based on current evidence.
• Stroke: Small increased risk with oral estrogen, not clearly seen with transdermal estrogen at standard doses.
• Initial side effects: Breast tenderness, bloating, spotting in the first few months. Usually temporary.
• Mood changes: Some women don't tolerate synthetic progestins well (irritability, low mood). Switching to micronized progesterone often resolves this.

The answer to most of these risks is not "avoid HRT." It's clinical supervision, appropriate formulation selection, and monitoring. Which is exactly what a real protocol provides.

How to Get Started with Menopause Treatment at Healthspan

Here's the honest version of what getting this right looks like: it starts with labs, not assumptions. Your symptoms give important context, but your hormone levels, metabolic markers, lipid panel, and medical history shape what's actually appropriate for you. That's why Healthspan's Women's Hormone Health program begins with comprehensive lab testing and a clinician consultation before anything is prescribed.

From there, the protocol is built around your specific picture. Hot flashes and night sweats driving you crazy? The Estradiol Patch or Bi-Est 50/50 Cream plus Micronized Progesterone are likely to be your core protocol. Struggling with body composition changes and metabolic risk? That might involve metabolic support through GLP-1 Longevity Care or Metformin alongside or instead of hormones. The point is that you get a protocol, not a product, with follow-up built in to adjust as your body responds.

If you're navigating menopause symptoms and want a clinical team that's actually read the evidence, start with a consultation at Healthspan.

Frequently Asked Questions About Menopause Treatments

Is HRT safe in 2025?

For most healthy women under 60 who are within 10 years of menopause onset, current evidence supports HRT as safe and effective. The 2002 WHI study that scared everyone used older formulations in an older population. Transdermal estrogen with micronized progesterone has a more favorable risk profile than the oral combined therapy studied in the WHI. That said, individual risk factors matter, and it should always be assessed with a clinician who knows your history.

What is the best non-hormonal treatment for menopause hot flashes?

The most effective non-hormonal option in 2025 is fezolinetant (Veozah), an FDA-approved neurokinin B receptor antagonist that reduced hot flash frequency by around 60% in clinical trials. Low-dose paroxetine is the other FDA-approved option, reducing frequency by roughly 40-60%. SSRIs like venlafaxine and escitalopram also have evidence. None of these are as effective as estrogen, but they're meaningful alternatives when HRT isn't appropriate.

What are the differences between estrogen patches, gels, and creams?

All three are transdermal delivery methods that bypass liver metabolism, which is a significant safety advantage over oral estrogen. The differences are practical: patches are applied 1-2 times per week and deliver consistent levels; gels and creams are applied daily and require a few minutes to dry. Bi-Est cream contains both estradiol and estriol, which some clinicians prefer for specific applications. The right choice depends on preference, skin sensitivity, and clinical factors.

Does menopause treatment help with weight gain?

HRT doesn't cause weight loss, but it can reduce the shift toward visceral fat accumulation that happens in menopause. It also preserves muscle mass indirectly by improving energy, sleep, and exercise tolerance. For women with significant weight gain or metabolic risk in menopause, GLP-1 receptor agonists may be appropriate adjuncts, addressing the metabolic changes that hormones alone don't fully reverse.

How long should you take HRT?

There's no fixed limit. The old "5-year rule" was based on the misinterpreted WHI data. Current guidance from the Menopause Society says duration should be individualized based on ongoing symptom burden, risk factors, and patient preference. Many women benefit from continuing HRT through their 60s if they started it early and tolerate it well. Annual review with your clinician is the standard of care.

Can menopause treatment improve brain fog and memory?

This is an active research area. Estrogen has neuroprotective effects, and the "timing hypothesis" suggests that starting HRT early in menopause may help preserve cognitive function. However, starting HRT more than 10 years after menopause may not carry the same benefit. The cognitive effects are more pronounced for perimenopausal women with significant vasomotor symptoms. It's promising evidence, but not yet a proven indication on its own.

What's the difference between bioidentical and conventional HRT?

Bioidentical simply means the hormone is structurally identical to what your body makes. Many FDA-approved HRT products, including estradiol patches and micronized progesterone, are bioidentical. The confusion arises with custom-compounded "bioidentical" hormone creams, which are not FDA-regulated and have no standardized evidence for safety or efficacy. FDA-approved bioidentical products are the recommended choice for most women.